<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02102932</url>
  </required_header>
  <id_info>
    <org_study_id>1276.23</org_study_id>
    <nct_id>NCT02102932</nct_id>
  </id_info>
  <brief_title>Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers</brief_title>
  <official_title>Relative Bioavailability of Empagliflozin (12.5 or 5 mg)/Metformin (850 mg or 500 mg) Fixed Dose Combination Tablets Compared to Single Tablets Administered Together to Healthy Chinese Male and Female Volunteers in an Open-label, Randomised, Single-dose, Two-way Crossover Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The aim of the trial is to assess the relative bioavailability of fixed dose combination
      tablets of Empagliflozin and metformin compared to the administration of single tablets
      (Empagliflozin and metformin ) in Chinese subjects. The availability of a fixed dose
      combination tablet is expected to significantly enhance patient's compliance with
      antidiabetic treatment, in particular with concern to the frequent polypharmacy in diabetic
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC(0-∞) for Empagliflozin</measure>
    <time_frame>1 hour (h) before drug administration and 20 min (m), 40m, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
    <description>Area under the concentration-time curve of the empagliflozin in plasma over the time interval from 0 extrapolated to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-∞) for Metformin</measure>
    <time_frame>1 hour (h) before drug administration and 20 min (m), 40m, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
    <description>Area under the concentration-time curve of the metformin in plasma over the time interval from 0 extrapolated to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for Empagliflozin</measure>
    <time_frame>1 hour (h) before drug administration and 20 min (m), 40m, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
    <description>Maximum measured concentration of the empagliflozin in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for Metformin</measure>
    <time_frame>1 hour (h) before drug administration and 20 min (m), 40m, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
    <description>Maximum measured concentration of the metformin in plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC(0-tz) of Empagliflozin</measure>
    <time_frame>1 hour (h) before drug administration and 20 min (m), 40m, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
    <description>Area under the concentration-time curve of the empagliflozin in plasma over the time interval from 0 up to the last quantifiable data point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-tz) of Metformin</measure>
    <time_frame>1 hour (h) before drug administration and 20 min (m), 40m, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
    <description>Area under the concentration-time curve of the metformin in plasma over the time interval from 0 up to the last quantifiable data point</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>12.5 mg empagliflozin/850 mg metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 12.5 mg empagliflozin/850 mg metformin and single 10 mg empagliflozin, 2.5 mg empagliflozin, 850 mg metformin tablets single dose in randomized order</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 mg empagliflozin/850 mg metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 5 mg empagliflozin/850 mg metformin and single Empagliflozin(5mg) and metformin (850mg) tablets single dose in randomized order</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12.5 mg empagliflozin/500 mg metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 12.5 mg empagliflozin/500 mg metformin and single 10 mg empagliflozin, 2.5 mg empagliflozin, 500 mg metformin tablets single dose in randomized order</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 mg empagliflozin/500 mg metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 subjects (12 male and 12 female) will be assigned to 2 treatment sequences. cross-over design was adopted to ensure each patient would take fixed dose combination tablets of 5 mg empagliflozin/500 mg metformin and single Empagliflozin(5mg) and metformin (500mg) tablets single dose in randomized order</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 mg empagliflozin/850 mg metformin FDC</intervention_name>
    <description>5 mg empagliflozin/850 mg metformin FDC</description>
    <arm_group_label>5 mg empagliflozin/850 mg metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>12.5 mg empagliflozin</intervention_name>
    <description>10 mg empagliflozin tablet and 2.5 mg empagliflozin tablet</description>
    <arm_group_label>12.5 mg empagliflozin/500 mg metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>12.5 mg empagliflozin</intervention_name>
    <description>10mg empagliflozin tablet and 2.5 mg empagliflozin tablet</description>
    <arm_group_label>12.5 mg empagliflozin/850 mg metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>850 mg metformin</intervention_name>
    <description>850mg metformin tablet</description>
    <arm_group_label>12.5 mg empagliflozin/850 mg metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 mg empagliflozin</intervention_name>
    <description>5 mg empagliflozin</description>
    <arm_group_label>5 mg empagliflozin/850 mg metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 mg empagliflozin</intervention_name>
    <description>5 mg empagliflozin</description>
    <arm_group_label>5 mg empagliflozin/500 mg metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>850 mg metformin</intervention_name>
    <description>850 mg metformin</description>
    <arm_group_label>5 mg empagliflozin/850 mg metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>12.5 mg empagliflozin/850 mg metformin FDC</intervention_name>
    <description>12.5 mg empagliflozin/850 mg metformin FDC</description>
    <arm_group_label>12.5 mg empagliflozin/850 mg metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>12.5 mg empagliflozin/500 mg metformin FDC</intervention_name>
    <description>12.5 mg empagliflozin/500 mg metformin FDC</description>
    <arm_group_label>12.5 mg empagliflozin/500 mg metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 mg empagliflozin/500 mg metformin FDC</intervention_name>
    <description>5 mg empagliflozin/500 mg metformin FDC</description>
    <arm_group_label>5 mg empagliflozin/500 mg metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>500 mg metformin</intervention_name>
    <description>500 mg metformin</description>
    <arm_group_label>12.5 mg empagliflozin/500 mg metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>500 mg metformin</intervention_name>
    <description>500 mg metformin</description>
    <arm_group_label>5 mg empagliflozin/500 mg metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Healthy male and female subjects

        Exclusion criteria:

        Any relevant deviation from healthy conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1276.23.86002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2014</study_first_submitted>
  <study_first_submitted_qc>March 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2014</study_first_posted>
  <results_first_submitted>August 21, 2015</results_first_submitted>
  <results_first_submitted_qc>August 21, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 24, 2015</results_first_posted>
  <last_update_submitted>August 21, 2015</last_update_submitted>
  <last_update_submitted_qc>August 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was performed as an open-label, randomised, single-dose, two-way crossover trial consisting of four trial parts. In each trial part the aim was to investigate the relative bioavailability of the Test treatment (T) and to compare it with the Reference treatment (R).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>T1R1</title>
          <description>Study Part 1:
T1: Oral administration of a single fixed dose combination (FDC) tablet 12.5 mg empagliflozin/850 mg metformin R1: Oral administration of 1 tablet empagliflozin 10 mg + 1 tablet empagliflozin 2.5 mg + 1 tablet Glucophage® 850 mg; A washout period of at least 7 days was to be maintained between T1 and R1.</description>
        </group>
        <group group_id="P2">
          <title>R1T1</title>
          <description>Study Part 1:
R1: Oral administration of 1 tablet empagliflozin 10 mg + 1 tablet empagliflozin 2.5 mg + 1 tablet Glucophage® 850 mg T1: Oral administration of a single FDC tablet 12.5 mg empagliflozin/850 mg metformin; A washout period of at least 7 days was to be maintained between R1 and T1.</description>
        </group>
        <group group_id="P3">
          <title>T2R2</title>
          <description>Study Part 2:
T2: Oral administration of a single FDC tablet 5 mg empagliflozin/850 mg metformin R2: Oral administration of 1 tablet empagliflozin 5 mg + 1 tablet Glucophage® 850 mg; A washout period of at least 7 days was to be maintained between T2 and R2.</description>
        </group>
        <group group_id="P4">
          <title>R2T2</title>
          <description>Study part 2:
R2: Oral administration of 1 tablet empagliflozin 5 mg + 1 tablet Glucophage® 850 mg; T2: Oral administration of a single FDC tablet 5 mg empagliflozin/850 mg metformin; A washout period of at least 7 days was to be maintained between R2 and T2.</description>
        </group>
        <group group_id="P5">
          <title>T3R3</title>
          <description>Study Part 3:
T3: Oral administration of a single FDC tablet 12.5 mg empagliflozin/500 mg metformin R3: Oral administration of 1 tablet empagliflozin 10 mg + 1 tablet empagliflozin 2.5 mg + 1 tablet Glucophage® 500 mg; A washout period of at least 7 days was to be maintained between T3 and R3.</description>
        </group>
        <group group_id="P6">
          <title>R3T3</title>
          <description>Study Part 3:
R3: Oral administration of 1 tablet empagliflozin 10 mg + 1 tablet empagliflozin 2.5 mg + 1 tablet Glucophage® 500 mg T3: Oral administration of a single FDC tablet 12.5 mg empagliflozin/500 mg metformin; A washout period of at least 7 days was to be maintained between R3 and T3</description>
        </group>
        <group group_id="P7">
          <title>T4R4</title>
          <description>Study Part 4:
T4: Oral administration of a single FDC tablet 5 mg empagliflozin/500 mg metformin R4: Oral administration of 1 tablet empagliflozin 5 mg + 1 tablet Glucophage® 500 mg; A washout period of at least 7 days was to be maintained between T4 and R4.</description>
        </group>
        <group group_id="P8">
          <title>R4T4</title>
          <description>Study Part 4:
R4: Oral administration of 1 tablet empagliflozin 5 mg + 1 tablet Glucophage® 500 mg; T4: Oral administration of a single FDC tablet 5 mg empagliflozin/500 mg metformin; A washout period of at least 7 days was to be maintained between R4 and T4</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set (TS): The TS included all subjects who were dispensed study medication and were documented to have received at least 1 dose of trial medication</population>
      <group_list>
        <group group_id="B1">
          <title>T1R1</title>
          <description>Study Part 1:
T1: Oral administration of a single fixed dose combination (FDC) tablet 12.5 mg empagliflozin/850 mg metformin R1: Oral administration of 1 tablet empagliflozin 10 mg + 1 tablet empagliflozin 2.5 mg + 1 tablet Glucophage® 850 mg; A washout period of at least 7 days was to be maintained between T1 and R1.</description>
        </group>
        <group group_id="B2">
          <title>R1T1</title>
          <description>Study Part 1:
R1: Oral administration of 1 tablet empagliflozin 10 mg + 1 tablet empagliflozin 2.5 mg + 1 tablet Glucophage® 850 mg T1: Oral administration of a single FDC tablet 12.5 mg empagliflozin/850 mg metformin; A washout period of at least 7 days was to be maintained between R1 and T1.</description>
        </group>
        <group group_id="B3">
          <title>T2R2</title>
          <description>Study Part 2:
T2: Oral administration of a single FDC tablet 5 mg empagliflozin/850 mg metformin R2: Oral administration of 1 tablet empagliflozin 5 mg + 1 tablet Glucophage® 850 mg; A washout period of at least 7 days was to be maintained between T2 and R2.</description>
        </group>
        <group group_id="B4">
          <title>R2T2</title>
          <description>Study part 2:
R2: Oral administration of 1 tablet empagliflozin 5 mg + 1 tablet Glucophage® 850 mg; T2: Oral administration of a single FDC tablet 5 mg empagliflozin/850 mg metformin; A washout period of at least 7 days was to be maintained between R2 and T2.</description>
        </group>
        <group group_id="B5">
          <title>T3R3</title>
          <description>Study Part 3:
T3: Oral administration of a single FDC tablet 12.5 mg empagliflozin/500 mg metformin R3: Oral administration of 1 tablet empagliflozin 10 mg + 1 tablet empagliflozin 2.5 mg + 1 tablet Glucophage® 500 mg; A washout period of at least 7 days was to be maintained between T3 and R3.</description>
        </group>
        <group group_id="B6">
          <title>R3T3</title>
          <description>Study Part 3:
R3: Oral administration of 1 tablet empagliflozin 10 mg + 1 tablet empagliflozin 2.5 mg + 1 tablet Glucophage® 500 mg T3: Oral administration of a single FDC tablet 12.5 mg empagliflozin/500 mg metformin; A washout period of at least 7 days was to be maintained between R3 and T3</description>
        </group>
        <group group_id="B7">
          <title>T4R4</title>
          <description>Study Part 4:
T4: Oral administration of a single FDC tablet 5 mg empagliflozin/500 mg metformin R4: Oral administration of 1 tablet empagliflozin 5 mg + 1 tablet Glucophage® 500 mg; A washout period of at least 7 days was to be maintained between T4 and R4.</description>
        </group>
        <group group_id="B8">
          <title>R4T4</title>
          <description>Study Part 4:
R4: Oral administration of 1 tablet empagliflozin 5 mg + 1 tablet Glucophage® 500 mg; T4: Oral administration of a single FDC tablet 5 mg empagliflozin/500 mg metformin; A washout period of at least 7 days was to be maintained between R4 and T4</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="12"/>
            <count group_id="B6" value="12"/>
            <count group_id="B7" value="12"/>
            <count group_id="B8" value="12"/>
            <count group_id="B9" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.9" spread="4.8"/>
                    <measurement group_id="B2" value="27.0" spread="5.3"/>
                    <measurement group_id="B3" value="26.8" spread="5.3"/>
                    <measurement group_id="B4" value="24.3" spread="3.4"/>
                    <measurement group_id="B5" value="24.8" spread="4.3"/>
                    <measurement group_id="B6" value="24.4" spread="3.9"/>
                    <measurement group_id="B7" value="24.6" spread="3.7"/>
                    <measurement group_id="B8" value="25.6" spread="4.8"/>
                    <measurement group_id="B9" value="25.5" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-∞) for Empagliflozin</title>
        <description>Area under the concentration-time curve of the empagliflozin in plasma over the time interval from 0 extrapolated to infinity</description>
        <time_frame>1 hour (h) before drug administration and 20 min (m), 40m, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
        <population>Pharmacokinetic set (PKS):
The PKS included all evaluable subjects of the TS who provided at least 1 observation for at least 1 primary PK endpoint in both treatment periods without Important protocol violations (IPV) relevant to the evaluation of PK.</population>
        <group_list>
          <group group_id="O1">
            <title>T1 (FDC)</title>
            <description>Oral administration of a single fixed dose combination (FDC) tablet 12.5 mg empagliflozin/850 mg metformin</description>
          </group>
          <group group_id="O2">
            <title>R1 (FC)</title>
            <description>Oral administration of free combination (FC) of 1 tablet empagliflozin 10 mg + 1 tablet empagliflozin 2.5 mg + 1 tablet Glucophage® 850 mg</description>
          </group>
          <group group_id="O3">
            <title>T2 (FDC)</title>
            <description>Oral administration of a single FDC tablet 5 mg empagliflozin/850 mg metformin</description>
          </group>
          <group group_id="O4">
            <title>R2 (FC)</title>
            <description>Oral administration of FC of 1 tablet empagliflozin 5 mg + 1 tablet Glucophage® 850 mg</description>
          </group>
          <group group_id="O5">
            <title>T3 (FDC)</title>
            <description>Oral administration of a single FDC tablet 12.5 mg empagliflozin/500 mg metformin</description>
          </group>
          <group group_id="O6">
            <title>R3 (FC)</title>
            <description>Oral administration of FC of 1 tablet empagliflozin 10 mg + 1 tablet empagliflozin 2.5 mg + 1 tablet Glucophage® 500 mg</description>
          </group>
          <group group_id="O7">
            <title>T4 (FDC)</title>
            <description>Oral administration of a single FDC tablet 5 mg empagliflozin/500 mg metformin</description>
          </group>
          <group group_id="O8">
            <title>R4 (FC)</title>
            <description>Oral administration of FC of 1 tablet empagliflozin 5 mg + 1 tablet Glucophage® 500 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-∞) for Empagliflozin</title>
          <description>Area under the concentration-time curve of the empagliflozin in plasma over the time interval from 0 extrapolated to infinity</description>
          <population>Pharmacokinetic set (PKS):
The PKS included all evaluable subjects of the TS who provided at least 1 observation for at least 1 primary PK endpoint in both treatment periods without Important protocol violations (IPV) relevant to the evaluation of PK.</population>
          <units>nmol * h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="24"/>
                <count group_id="O8" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4330" spread="16.6"/>
                    <measurement group_id="O2" value="4110" spread="15.3"/>
                    <measurement group_id="O3" value="1680" spread="22.0"/>
                    <measurement group_id="O4" value="1630" spread="21.1"/>
                    <measurement group_id="O5" value="4200" spread="20.3"/>
                    <measurement group_id="O6" value="4060" spread="18.6"/>
                    <measurement group_id="O7" value="1610" spread="16.5"/>
                    <measurement group_id="O8" value="1560" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical model used was an analysis of variance (ANOVA) model on the logarithmic scale. This model included effects accounting for the following sources of variation:
‘sequence’, ‘subjects within sequences’, ‘period’ and ‘treatment’. The effect ‘subjects within sequences’ was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0000</p_value>
            <p_value_desc>P-value for ratio outside interval 80-125</p_value_desc>
            <method>ANOVA</method>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>105.29</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>6.6</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>101.92</ci_lower_limit>
            <ci_upper_limit>108.78</ci_upper_limit>
            <estimate_desc>Ratio of the geometric means for treatments (Test (T1) versus Reference (R1)) i.e. T1/R1. The standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The statistical model used was an analysis of variance (ANOVA) model on the logarithmic scale. This model included effects accounting for the following sources of variation:
‘sequence’, ‘subjects within sequences’, ‘period’ and ‘treatment’. The effect ‘subjects within sequences’ was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0000</p_value>
            <p_value_desc>P-value for ratio outside interval 80-125</p_value_desc>
            <method>ANOVA</method>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>103.23</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>6.6</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.91</ci_lower_limit>
            <ci_upper_limit>106.65</ci_upper_limit>
            <estimate_desc>Ratio of the geometric means for treatments (Test (T2) versus Reference (R2)) i.e. T2/R2. The standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The statistical model used was an analysis of variance (ANOVA) model on the logarithmic scale. This model included effects accounting for the following sources of variation:
‘sequence’, ‘subjects within sequences’, ‘period’ and ‘treatment’. The effect ‘subjects within sequences’ was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0000</p_value>
            <p_value_desc>P-value for ratio outside interval 80-125</p_value_desc>
            <method>ANOVA</method>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>103.56</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>7.6</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.73</ci_lower_limit>
            <ci_upper_limit>107.54</ci_upper_limit>
            <estimate_desc>Ratio of the geometric means for treatments (Test (T3) versus Reference (R3)) i.e. T3/R3. The standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>The statistical model used was an analysis of variance (ANOVA) model on the logarithmic scale. This model included effects accounting for the following sources of variation:
‘sequence’, ‘subjects within sequences’, ‘period’ and ‘treatment’. The effect ‘subjects within sequences’ was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0000</p_value>
            <p_value_desc>P-value for ratio outside interval 80-125</p_value_desc>
            <method>ANOVA</method>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>102.81</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>6.9</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.36</ci_lower_limit>
            <ci_upper_limit>106.37</ci_upper_limit>
            <estimate_desc>Ratio of the geometric means for treatments (Test (T4) versus Reference (R4)) i.e. T4/R4. The standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(0-∞) for Metformin</title>
        <description>Area under the concentration-time curve of the metformin in plasma over the time interval from 0 extrapolated to infinity</description>
        <time_frame>1 hour (h) before drug administration and 20 min (m), 40m, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
        <population>Pharmacokinetic set (PKS):
The PKS included all evaluable subjects of the TS who provided at least 1 observation for at least 1 primary PK endpoint in both treatment periods without Important protocol violations (IPV) relevant to the evaluation of PK.</population>
        <group_list>
          <group group_id="O1">
            <title>T1 (FDC)</title>
            <description>Oral administration of a single fixed dose combination (FDC) tablet 12.5 mg empagliflozin/850 mg metformin</description>
          </group>
          <group group_id="O2">
            <title>R1 (FC)</title>
            <description>Oral administration of free combination (FC) of 1 tablet empagliflozin 10 mg + 1 tablet empagliflozin 2.5 mg + 1 tablet Glucophage® 850 mg</description>
          </group>
          <group group_id="O3">
            <title>T2 (FDC)</title>
            <description>Oral administration of a single FDC tablet 5 mg empagliflozin/850 mg metformin</description>
          </group>
          <group group_id="O4">
            <title>R2 (FC)</title>
            <description>Oral administration of FC of 1 tablet empagliflozin 5 mg + 1 tablet Glucophage® 850 mg</description>
          </group>
          <group group_id="O5">
            <title>T3 (FDC)</title>
            <description>Oral administration of a single FDC tablet 12.5 mg empagliflozin/500 mg metformin</description>
          </group>
          <group group_id="O6">
            <title>R3 (FC)</title>
            <description>Oral administration of FC of 1 tablet empagliflozin 10 mg + 1 tablet empagliflozin 2.5 mg + 1 tablet Glucophage® 500 mg</description>
          </group>
          <group group_id="O7">
            <title>T4 (FDC)</title>
            <description>Oral administration of a single FDC tablet 5 mg empagliflozin/500 mg metformin</description>
          </group>
          <group group_id="O8">
            <title>R4 (FC)</title>
            <description>Oral administration of FC of 1 tablet empagliflozin 5 mg + 1 tablet Glucophage® 500 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-∞) for Metformin</title>
          <description>Area under the concentration-time curve of the metformin in plasma over the time interval from 0 extrapolated to infinity</description>
          <population>Pharmacokinetic set (PKS):
The PKS included all evaluable subjects of the TS who provided at least 1 observation for at least 1 primary PK endpoint in both treatment periods without Important protocol violations (IPV) relevant to the evaluation of PK.</population>
          <units>ng * h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="24"/>
                <count group_id="O8" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11600" spread="18.9"/>
                    <measurement group_id="O2" value="11100" spread="17.4"/>
                    <measurement group_id="O3" value="11700" spread="21.8"/>
                    <measurement group_id="O4" value="11000" spread="24.0"/>
                    <measurement group_id="O5" value="7800" spread="18.9"/>
                    <measurement group_id="O6" value="7510" spread="17.8"/>
                    <measurement group_id="O7" value="7030" spread="20.7"/>
                    <measurement group_id="O8" value="7340" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical model used was an analysis of variance (ANOVA) model on the logarithmic scale. This model included effects accounting for the following sources of variation:
‘sequence’, ‘subjects within sequences’, ‘period’ and ‘treatment’. The effect ‘subjects within sequences’ was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>P-value for ratio outside interval 80-125</p_value_desc>
            <method>ANOVA</method>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>104.56</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>14.0</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.56</ci_lower_limit>
            <ci_upper_limit>112.07</ci_upper_limit>
            <estimate_desc>Ratio of the geometric means for treatments (Test (T1) versus Reference (R1)) i.e. T1/R1. The standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The statistical model used was an analysis of variance (ANOVA) model on the logarithmic scale. This model included effects accounting for the following sources of variation:
‘sequence’, ‘subjects within sequences’, ‘period’ and ‘treatment’. The effect ‘subjects within sequences’ was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>P-value for ratio outside interval 80-125</p_value_desc>
            <method>ANOVA</method>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>105.80</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>12.8</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.32</ci_lower_limit>
            <ci_upper_limit>112.70</ci_upper_limit>
            <estimate_desc>Ratio of the geometric means for treatments (Test (T2) versus Reference (R2)) i.e. T2/R2. The standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The statistical model used was an analysis of variance (ANOVA) model on the logarithmic scale. This model included effects accounting for the following sources of variation:
‘sequence’, ‘subjects within sequences’, ‘period’ and ‘treatment’. The effect ‘subjects within sequences’ was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0000</p_value>
            <p_value_desc>P-value for ratio outside interval 80-125</p_value_desc>
            <method>ANOVA</method>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>103.75</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>11.2</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.18</ci_lower_limit>
            <ci_upper_limit>109.63</ci_upper_limit>
            <estimate_desc>Ratio of the geometric means for treatments (Test (T3) versus Reference (R3)) i.e. T3/R3. The standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>The statistical model used was an analysis of variance (ANOVA) model on the logarithmic scale. This model included effects accounting for the following sources of variation:
‘sequence’, ‘subjects within sequences’, ‘period’ and ‘treatment’. The effect ‘subjects within sequences’ was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0000</p_value>
            <p_value_desc>P-value for ratio outside interval 80-125</p_value_desc>
            <method>ANOVA</method>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>95.77</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>12.8</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>89.88</ci_lower_limit>
            <ci_upper_limit>102.03</ci_upper_limit>
            <estimate_desc>Ratio of the geometric means for treatments (Test (T4) versus Reference (R4)) i.e. T4/R4. The standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax for Empagliflozin</title>
        <description>Maximum measured concentration of the empagliflozin in plasma</description>
        <time_frame>1 hour (h) before drug administration and 20 min (m), 40m, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
        <population>Pharmacokinetic set (PKS):
The PKS included all evaluable subjects of the TS who provided at least 1 observation for at least 1 primary PK endpoint in both treatment periods without Important protocol violations (IPV) relevant to the evaluation of PK.</population>
        <group_list>
          <group group_id="O1">
            <title>T1 (FDC)</title>
            <description>Oral administration of a single fixed dose combination (FDC) tablet 12.5 mg empagliflozin/850 mg metformin</description>
          </group>
          <group group_id="O2">
            <title>R1 (FC)</title>
            <description>Oral administration of free combination (FC) of 1 tablet empagliflozin 10 mg + 1 tablet empagliflozin 2.5 mg + 1 tablet Glucophage® 850 mg</description>
          </group>
          <group group_id="O3">
            <title>T2 (FDC)</title>
            <description>Oral administration of a single FDC tablet 5 mg empagliflozin/850 mg metformin</description>
          </group>
          <group group_id="O4">
            <title>R2 (FC)</title>
            <description>Oral administration of FC of 1 tablet empagliflozin 5 mg + 1 tablet Glucophage® 850 mg</description>
          </group>
          <group group_id="O5">
            <title>T3 (FDC)</title>
            <description>Oral administration of a single FDC tablet 12.5 mg empagliflozin/500 mg metformin</description>
          </group>
          <group group_id="O6">
            <title>R3 (FC)</title>
            <description>Oral administration of FC of 1 tablet empagliflozin 10 mg + 1 tablet empagliflozin 2.5 mg + 1 tablet Glucophage® 500 mg</description>
          </group>
          <group group_id="O7">
            <title>T4 (FDC)</title>
            <description>Oral administration of a single FDC tablet 5 mg empagliflozin/500 mg metformin</description>
          </group>
          <group group_id="O8">
            <title>R4 (FC)</title>
            <description>Oral administration of FC of 1 tablet empagliflozin 5 mg + 1 tablet Glucophage® 500 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax for Empagliflozin</title>
          <description>Maximum measured concentration of the empagliflozin in plasma</description>
          <population>Pharmacokinetic set (PKS):
The PKS included all evaluable subjects of the TS who provided at least 1 observation for at least 1 primary PK endpoint in both treatment periods without Important protocol violations (IPV) relevant to the evaluation of PK.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="24"/>
                <count group_id="O8" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="644" spread="18.2"/>
                    <measurement group_id="O2" value="605" spread="15.3"/>
                    <measurement group_id="O3" value="263" spread="17.7"/>
                    <measurement group_id="O4" value="237" spread="20.7"/>
                    <measurement group_id="O5" value="569" spread="22.1"/>
                    <measurement group_id="O6" value="561" spread="25.3"/>
                    <measurement group_id="O7" value="228" spread="16.4"/>
                    <measurement group_id="O8" value="221" spread="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical model used was an analysis of variance (ANOVA) model on the logarithmic scale. This model included effects accounting for the following sources of variation:
‘sequence’, ‘subjects within sequences’, ‘period’ and ‘treatment’. The effect ‘subjects within sequences’ was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0000</p_value>
            <p_value_desc>P-value for ratio outside interval 80-125</p_value_desc>
            <method>ANOVA</method>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>106.44</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>11.8</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>100.44</ci_lower_limit>
            <ci_upper_limit>112.80</ci_upper_limit>
            <estimate_desc>Ratio of the geometric means for treatments (Test (T1) versus Reference (R1)) i.e. T1/R1. The standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The statistical model used was an analysis of variance (ANOVA) model on the logarithmic scale. This model included effects accounting for the following sources of variation:
‘sequence’, ‘subjects within sequences’, ‘period’ and ‘treatment’. The effect ‘subjects within sequences’ was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0021</p_value>
            <p_value_desc>P-value for ratio outside interval 80-125</p_value_desc>
            <method>ANOVA</method>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>110.78</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>13.2</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>103.80</ci_lower_limit>
            <ci_upper_limit>118.24</ci_upper_limit>
            <estimate_desc>Ratio of the geometric means for treatments (Test (T2) versus Reference (R2)) i.e. T2/R2. The standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The statistical model used was an analysis of variance (ANOVA) model on the logarithmic scale. This model included effects accounting for the following sources of variation:
‘sequence’, ‘subjects within sequences’, ‘period’ and ‘treatment’. The effect ‘subjects within sequences’ was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0000</p_value>
            <p_value_desc>P-value for ratio outside interval 80-125</p_value_desc>
            <method>ANOVA</method>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>101.38</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>13.6</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.82</ci_lower_limit>
            <ci_upper_limit>108.39</ci_upper_limit>
            <estimate_desc>Ratio of the geometric means for treatments (Test (T3) versus Reference (R3)) i.e. T3/R3. The standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>The statistical model used was an analysis of variance (ANOVA) model on the logarithmic scale. This model included effects accounting for the following sources of variation:
‘sequence’, ‘subjects within sequences’, ‘period’ and ‘treatment’. The effect ‘subjects within sequences’ was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>P-value for ratio outside interval 80-125</p_value_desc>
            <method>ANOVA</method>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>103.02</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>16.3</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>95.08</ci_lower_limit>
            <ci_upper_limit>111.63</ci_upper_limit>
            <estimate_desc>Ratio of the geometric means for treatments (Test (T4) versus Reference (R4)) i.e. T4/R4. The standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax for Metformin</title>
        <description>Maximum measured concentration of the metformin in plasma</description>
        <time_frame>1 hour (h) before drug administration and 20 min (m), 40m, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
        <population>Pharmacokinetic set (PKS):
The PKS included all evaluable subjects of the TS who provided at least 1 observation for at least 1 primary PK endpoint in both treatment periods without Important protocol violations (IPV) relevant to the evaluation of PK.</population>
        <group_list>
          <group group_id="O1">
            <title>T1 (FDC)</title>
            <description>Oral administration of a single fixed dose combination (FDC) tablet 12.5 mg empagliflozin/850 mg metformin</description>
          </group>
          <group group_id="O2">
            <title>R1 (FC)</title>
            <description>Oral administration of free combination (FC) of 1 tablet empagliflozin 10 mg + 1 tablet empagliflozin 2.5 mg + 1 tablet Glucophage® 850 mg</description>
          </group>
          <group group_id="O3">
            <title>T2 (FDC)</title>
            <description>Oral administration of a single FDC tablet 5 mg empagliflozin/850 mg metformin</description>
          </group>
          <group group_id="O4">
            <title>R2 (FC)</title>
            <description>Oral administration of FC of 1 tablet empagliflozin 5 mg + 1 tablet Glucophage® 850 mg</description>
          </group>
          <group group_id="O5">
            <title>T3 (FDC)</title>
            <description>Oral administration of a single FDC tablet 12.5 mg empagliflozin/500 mg metformin</description>
          </group>
          <group group_id="O6">
            <title>R3 (FC)</title>
            <description>Oral administration of FC of 1 tablet empagliflozin 10 mg + 1 tablet empagliflozin 2.5 mg + 1 tablet Glucophage® 500 mg</description>
          </group>
          <group group_id="O7">
            <title>T4 (FDC)</title>
            <description>Oral administration of a single FDC tablet 5 mg empagliflozin/500 mg metformin</description>
          </group>
          <group group_id="O8">
            <title>R4 (FC)</title>
            <description>Oral administration of FC of 1 tablet empagliflozin 5 mg + 1 tablet Glucophage® 500 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax for Metformin</title>
          <description>Maximum measured concentration of the metformin in plasma</description>
          <population>Pharmacokinetic set (PKS):
The PKS included all evaluable subjects of the TS who provided at least 1 observation for at least 1 primary PK endpoint in both treatment periods without Important protocol violations (IPV) relevant to the evaluation of PK.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="24"/>
                <count group_id="O8" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1920" spread="20.9"/>
                    <measurement group_id="O2" value="1830" spread="16.6"/>
                    <measurement group_id="O3" value="1950" spread="26.4"/>
                    <measurement group_id="O4" value="1840" spread="26.0"/>
                    <measurement group_id="O5" value="1290" spread="22.2"/>
                    <measurement group_id="O6" value="1230" spread="27.1"/>
                    <measurement group_id="O7" value="1150" spread="25.5"/>
                    <measurement group_id="O8" value="1190" spread="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical model used was an analysis of variance (ANOVA) model on the logarithmic scale. This model included effects accounting for the following sources of variation:
‘sequence’, ‘subjects within sequences’, ‘period’ and ‘treatment’. The effect ‘subjects within sequences’ was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0000</p_value>
            <p_value_desc>P-value for ratio outside interval 80-125</p_value_desc>
            <method>ANOVA</method>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>104.91</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>11.2</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.29</ci_lower_limit>
            <ci_upper_limit>110.86</ci_upper_limit>
            <estimate_desc>Ratio of the geometric means for treatments (Test (T1) versus Reference (R1)) i.e. T1/R1. The standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The statistical model used was an analysis of variance (ANOVA) model on the logarithmic scale. This model included effects accounting for the following sources of variation:
‘sequence’, ‘subjects within sequences’, ‘period’ and ‘treatment’. The effect ‘subjects within sequences’ was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <p_value_desc>P-value for ratio outside interval 80-125</p_value_desc>
            <method>ANOVA</method>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>106.32</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>15.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>98.39</ci_lower_limit>
            <ci_upper_limit>114.88</ci_upper_limit>
            <estimate_desc>Ratio of the geometric means for treatments (Test (T2) versus Reference (R2)) i.e. T2/R2. The standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The statistical model used was an analysis of variance (ANOVA) model on the logarithmic scale. This model included effects accounting for the following sources of variation:
‘sequence’, ‘subjects within sequences’, ‘period’ and ‘treatment’. The effect ‘subjects within sequences’ was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>P-value for ratio outside interval 80-125</p_value_desc>
            <method>ANOVA</method>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>104.44</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>15.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>96.68</ci_lower_limit>
            <ci_upper_limit>112.82</ci_upper_limit>
            <estimate_desc>Ratio of the geometric means for treatments (Test (T3) versus Reference (R3)) i.e. T3/R3. The standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>The statistical model used was an analysis of variance (ANOVA) model on the logarithmic scale. This model included effects accounting for the following sources of variation:
‘sequence’, ‘subjects within sequences’, ‘period’ and ‘treatment’. The effect ‘subjects within sequences’ was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <p_value_desc>P-value for ratio outside interval 80-125</p_value_desc>
            <method>ANOVA</method>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>96.61</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>16.9</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.90</ci_lower_limit>
            <ci_upper_limit>104.99</ci_upper_limit>
            <estimate_desc>Ratio of the geometric means for treatments (Test (T4) versus Reference (R4)) i.e. T4/R4. The standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-tz) of Empagliflozin</title>
        <description>Area under the concentration-time curve of the empagliflozin in plasma over the time interval from 0 up to the last quantifiable data point</description>
        <time_frame>1 hour (h) before drug administration and 20 min (m), 40m, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
        <population>Pharmacokinetic set (PKS):
The PKS included all evaluable subjects of the TS who provided at least 1 observation for at least 1 primary PK endpoint in both treatment periods without Important protocol violations (IPV) relevant to the evaluation of PK.</population>
        <group_list>
          <group group_id="O1">
            <title>T1 (FDC)</title>
            <description>Oral administration of a single fixed dose combination (FDC) tablet 12.5 mg empagliflozin/850 mg metformin</description>
          </group>
          <group group_id="O2">
            <title>R1 (FC)</title>
            <description>Oral administration of free combination (FC) of 1 tablet empagliflozin 10 mg + 1 tablet empagliflozin 2.5 mg + 1 tablet Glucophage® 850 mg</description>
          </group>
          <group group_id="O3">
            <title>T2 (FDC)</title>
            <description>Oral administration of a single FDC tablet 5 mg empagliflozin/850 mg metformin</description>
          </group>
          <group group_id="O4">
            <title>R2 (FC)</title>
            <description>Oral administration of FC of 1 tablet empagliflozin 5 mg + 1 tablet Glucophage® 850 mg</description>
          </group>
          <group group_id="O5">
            <title>T3 (FDC)</title>
            <description>Oral administration of a single FDC tablet 12.5 mg empagliflozin/500 mg metformin</description>
          </group>
          <group group_id="O6">
            <title>R3 (FC)</title>
            <description>Oral administration of FC of 1 tablet empagliflozin 10 mg + 1 tablet empagliflozin 2.5 mg + 1 tablet Glucophage® 500 mg</description>
          </group>
          <group group_id="O7">
            <title>T4 (FDC)</title>
            <description>Oral administration of a single FDC tablet 5 mg empagliflozin/500 mg metformin</description>
          </group>
          <group group_id="O8">
            <title>R4 (FC)</title>
            <description>Oral administration of FC of 1 tablet empagliflozin 5 mg + 1 tablet Glucophage® 500 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-tz) of Empagliflozin</title>
          <description>Area under the concentration-time curve of the empagliflozin in plasma over the time interval from 0 up to the last quantifiable data point</description>
          <population>Pharmacokinetic set (PKS):
The PKS included all evaluable subjects of the TS who provided at least 1 observation for at least 1 primary PK endpoint in both treatment periods without Important protocol violations (IPV) relevant to the evaluation of PK.</population>
          <units>nmol * h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="24"/>
                <count group_id="O8" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4270" spread="16.6"/>
                    <measurement group_id="O2" value="4060" spread="14.7"/>
                    <measurement group_id="O3" value="1650" spread="21.5"/>
                    <measurement group_id="O4" value="1600" spread="21.0"/>
                    <measurement group_id="O5" value="4140" spread="19.7"/>
                    <measurement group_id="O6" value="4010" spread="18.5"/>
                    <measurement group_id="O7" value="1580" spread="16.7"/>
                    <measurement group_id="O8" value="1540" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical model used was an analysis of variance (ANOVA) model on the logarithmic scale. This model included effects accounting for the following sources of variation:
‘sequence’, ‘subjects within sequences’, ‘period’ and ‘treatment’. The effect ‘subjects within sequences’ was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0000</p_value>
            <p_value_desc>P-value for ratio outside interval 80-125</p_value_desc>
            <method>ANOVA</method>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>105.16</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>6.2</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>101.97</ci_lower_limit>
            <ci_upper_limit>108.45</ci_upper_limit>
            <estimate_desc>Ratio of the geometric means for treatments (Test (T1) versus Reference (R1)) i.e. T1/R1. The standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The statistical model used was an analysis of variance (ANOVA) model on the logarithmic scale. This model included effects accounting for the following sources of variation:
‘sequence’, ‘subjects within sequences’, ‘period’ and ‘treatment’. The effect ‘subjects within sequences’ was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0000</p_value>
            <p_value_desc>P-value for ratio outside interval 80-125</p_value_desc>
            <method>ANOVA</method>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>103.07</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>6.6</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.75</ci_lower_limit>
            <ci_upper_limit>106.50</ci_upper_limit>
            <estimate_desc>Ratio of the geometric means for treatments (Test (T2) versus Reference (R2)) i.e. T2/R2. The standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The statistical model used was an analysis of variance (ANOVA) model on the logarithmic scale. This model included effects accounting for the following sources of variation:
‘sequence’, ‘subjects within sequences’, ‘period’ and ‘treatment’. The effect ‘subjects within sequences’ was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0000</p_value>
            <p_value_desc>P-value for ratio outside interval 80-125</p_value_desc>
            <method>ANOVA</method>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>103.14</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>7.5</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.37</ci_lower_limit>
            <ci_upper_limit>107.04</ci_upper_limit>
            <estimate_desc>Ratio of the geometric means for treatments (Test (T3) versus Reference (R3)) i.e. T3/R3. The standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>The statistical model used was an analysis of variance (ANOVA) model on the logarithmic scale. This model included effects accounting for the following sources of variation:
‘sequence’, ‘subjects within sequences’, ‘period’ and ‘treatment’. The effect ‘subjects within sequences’ was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0000</p_value>
            <p_value_desc>P-value for ratio outside interval 80-125</p_value_desc>
            <method>ANOVA</method>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>102.61</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>7.0</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.10</ci_lower_limit>
            <ci_upper_limit>106.25</ci_upper_limit>
            <estimate_desc>Ratio of the geometric means for treatments (Test (T4) versus Reference (R4)) i.e. T4/R4. The standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0-tz) of Metformin</title>
        <description>Area under the concentration-time curve of the metformin in plasma over the time interval from 0 up to the last quantifiable data point</description>
        <time_frame>1 hour (h) before drug administration and 20 min (m), 40m, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration</time_frame>
        <population>Pharmacokinetic set (PKS):
The PKS included all evaluable subjects of the TS who provided at least 1 observation for at least 1 primary PK endpoint in both treatment periods without Important protocol violations (IPV) relevant to the evaluation of PK.</population>
        <group_list>
          <group group_id="O1">
            <title>T1 (FDC)</title>
            <description>Oral administration of a single fixed dose combination (FDC) tablet 12.5 mg empagliflozin/850 mg metformin</description>
          </group>
          <group group_id="O2">
            <title>R1 (FC)</title>
            <description>Oral administration of free combination (FC) of 1 tablet empagliflozin 10 mg + 1 tablet empagliflozin 2.5 mg + 1 tablet Glucophage® 850 mg</description>
          </group>
          <group group_id="O3">
            <title>T2 (FDC)</title>
            <description>Oral administration of a single FDC tablet 5 mg empagliflozin/850 mg metformin</description>
          </group>
          <group group_id="O4">
            <title>R2 (FC)</title>
            <description>Oral administration of FC of 1 tablet empagliflozin 5 mg + 1 tablet Glucophage® 850 mg</description>
          </group>
          <group group_id="O5">
            <title>T3 (FDC)</title>
            <description>Oral administration of a single FDC tablet 12.5 mg empagliflozin/500 mg metformin</description>
          </group>
          <group group_id="O6">
            <title>R3 (FC)</title>
            <description>Oral administration of FC of 1 tablet empagliflozin 10 mg + 1 tablet empagliflozin 2.5 mg + 1 tablet Glucophage® 500 mg</description>
          </group>
          <group group_id="O7">
            <title>T4 (FDC)</title>
            <description>Oral administration of a single FDC tablet 5 mg empagliflozin/500 mg metformin</description>
          </group>
          <group group_id="O8">
            <title>R4 (FC)</title>
            <description>Oral administration of FC of 1 tablet empagliflozin 5 mg + 1 tablet Glucophage® 500 mg</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0-tz) of Metformin</title>
          <description>Area under the concentration-time curve of the metformin in plasma over the time interval from 0 up to the last quantifiable data point</description>
          <population>Pharmacokinetic set (PKS):
The PKS included all evaluable subjects of the TS who provided at least 1 observation for at least 1 primary PK endpoint in both treatment periods without Important protocol violations (IPV) relevant to the evaluation of PK.</population>
          <units>ng* h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="24"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="24"/>
                <count group_id="O8" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11400" spread="19.2"/>
                    <measurement group_id="O2" value="10800" spread="17.6"/>
                    <measurement group_id="O3" value="11400" spread="23.1"/>
                    <measurement group_id="O4" value="10800" spread="25.1"/>
                    <measurement group_id="O5" value="7630" spread="18.9"/>
                    <measurement group_id="O6" value="7420" spread="17.9"/>
                    <measurement group_id="O7" value="6790" spread="24.7"/>
                    <measurement group_id="O8" value="7230" spread="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical model used was an analysis of variance (ANOVA) model on the logarithmic scale. This model included effects accounting for the following sources of variation:
‘sequence’, ‘subjects within sequences’, ‘period’ and ‘treatment’. The effect ‘subjects within sequences’ was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0000</p_value>
            <p_value_desc>P-value for ratio outside interval 80-125</p_value_desc>
            <method>ANOVA</method>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>105.33</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>11.9</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.34</ci_lower_limit>
            <ci_upper_limit>111.68</ci_upper_limit>
            <estimate_desc>Ratio of the geometric means for treatments (Test (T1) versus Reference (R1)) i.e. T1/R1. The standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The statistical model used was an analysis of variance (ANOVA) model on the logarithmic scale. This model included effects accounting for the following sources of variation:
‘sequence’, ‘subjects within sequences’, ‘period’ and ‘treatment’. The effect ‘subjects within sequences’ was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>P-value for ratio outside interval 80-125</p_value_desc>
            <method>ANOVA</method>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>105.75</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>13.2</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>99.09</ci_lower_limit>
            <ci_upper_limit>112.85</ci_upper_limit>
            <estimate_desc>Ratio of the geometric means for treatments (Test (T2) versus Reference (R2)) i.e. T2/R2. The standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>The statistical model used was an analysis of variance (ANOVA) model on the logarithmic scale. This model included effects accounting for the following sources of variation:
‘sequence’, ‘subjects within sequences’, ‘period’ and ‘treatment’. The effect ‘subjects within sequences’ was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0000</p_value>
            <p_value_desc>P-value for ratio outside interval 80-125</p_value_desc>
            <method>ANOVA</method>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>102.90</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>11.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.11</ci_lower_limit>
            <ci_upper_limit>109.03</ci_upper_limit>
            <estimate_desc>Ratio of the geometric means for treatments (Test (T3) versus Reference (R3)) i.e. T3/R3. The standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>The statistical model used was an analysis of variance (ANOVA) model on the logarithmic scale. This model included effects accounting for the following sources of variation:
‘sequence’, ‘subjects within sequences’, ‘period’ and ‘treatment’. The effect ‘subjects within sequences’ was considered as random, whereas the other effects were considered as fixed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>P-value for ratio outside interval 80-125</p_value_desc>
            <method>ANOVA</method>
            <param_type>Ratio of the geometric means</param_type>
            <param_value>93.84</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>13.6</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87.74</ci_lower_limit>
            <ci_upper_limit>100.36</ci_upper_limit>
            <estimate_desc>Ratio of the geometric means for treatments (Test (T4) versus Reference (R4)) i.e. T4/R4. The standard deviation is actually the intra-individual gCV.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First drug administration until 7 days after last drug administration, up to 8 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>T1 (FDC)</title>
          <description>Oral administration of a single fixed dose combination (FDC) tablet 12.5 mg empagliflozin/850 mg metformin</description>
        </group>
        <group group_id="E2">
          <title>R1 (FC)</title>
          <description>Oral administration of free combination (FC) of 1 tablet empagliflozin 10 mg + 1 tablet empagliflozin 2.5 mg + 1 tablet Glucophage® 850 mg</description>
        </group>
        <group group_id="E3">
          <title>T2 (FDC)</title>
          <description>Oral administration of a single FDC tablet 5 mg empagliflozin/850 mg metformin</description>
        </group>
        <group group_id="E4">
          <title>R2 (FC)</title>
          <description>Oral administration of FC of 1 tablet empagliflozin 5 mg + 1 tablet Glucophage® 850 mg</description>
        </group>
        <group group_id="E5">
          <title>T3 (FDC)</title>
          <description>Oral administration of a single FDC tablet 12.5 mg empagliflozin/500 mg metformin</description>
        </group>
        <group group_id="E6">
          <title>R3 (FC)</title>
          <description>Oral administration of FC of 1 tablet empagliflozin 10 mg + 1 tablet empagliflozin 2.5 mg + 1 tablet Glucophage® 500 mg</description>
        </group>
        <group group_id="E7">
          <title>T4 (FDC)</title>
          <description>Oral administration of a single FDC tablet 5 mg empagliflozin/500 mg metformin</description>
        </group>
        <group group_id="E8">
          <title>R4 (FC)</title>
          <description>Oral administration of FC of 1 tablet empagliflozin 5 mg + 1 tablet Glucophage® 500 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Bilirubin conjugated increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Blood bilirubin unconjugated increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Glucose urine present</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>800-243-0127 ext +1</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

